The CnOpenData Chemical Drug Catalog and Package Insert Database encompasses core catalog information and corresponding package inserts for marketed chemical drugs in China. This database includes key fields such as Active Ingredient (中英文), Drug Name (中英文), Brand Name (中英文), Dosage Form, Route of Administration, Strength, Reference Product Identifier, ATC Code, Approval Number/Registration Certificate Number, Approval Date, Marketing Authorization Holder (MAH), Manufacturer, Marketing Status, Inclusion Category, along with associated package insert attachment names and content IDs. It provides a comprehensive information chain—from drug components to market entry, and from official catalogs to detailed package inserts—facilitating systematic data support for drug R&D, market access, clinical medication, and policy analysis.

Database Features:

• Comprehensive Coverage of Key Drug Lifecycle Stages: Beyond basic information (active ingredients, dosage forms, strengths), the database records approval numbers, approval dates, MAHs, manufacturers, and marketing statuses. Users can trace a drug's lifecycle from registration to post-marketing phases, enabling applications in generic drug consistency evaluations and drug supply stability monitoring.
• Integrated Reference Products and ATC Codes for Cross-Drug Comparison: Each drug is annotated with its reference product status and assigned the WHO's Anatomical Therapeutic Chemical (ATC) code. Researchers can swiftly identify reference products for bioequivalence studies or analyze drug distributions across therapeutic areas via ATC classifications, supporting drug utilization and healthcare insurance formulary optimization.
• Linked Package Insert Content for Enhanced Clinical and R&D Efficiency: Attachment names and content IDs enable direct access to original package inserts. Users can retrieve critical clinical information (indications, usage/dosage, adverse reactions, contraindications) without multi-platform searches, significantly improving drug assessment and data extraction efficiency.

Application Value:

• Empowering Generic Drug R&D and Consistency Evaluation: The "Reference Product" identifier, combined with active ingredients, dosage forms, and strengths, allows rapid identification of target reference products and their market status. Analysis of approval timelines across manufacturers using approval numbers and MAH data further informs project initiation and regulatory strategies.
• Supporting Healthcare Policy and Reimbursement Research: ATC codes and marketing status fields enable statistical analyses of drug distributions by therapeutic area and sales status. This facilitates impact assessments of policies like volume-based procurement and reimbursement negotiations (e.g., quantifying shifts in reference-to-generic ratios within ATC categories to measure policy-driven accessibility improvements).
• Guiding Clinical Medication and Prescribing Decisions: Linked package inserts provide key details on indications, usage/dosage, contraindications, and drug interactions. Clinicians and pharmacists can compare inserts across brand names for a given active ingredient, supporting optimal treatment selection and reducing medication error risks.
• Promoting Drug Information Standardization and Data Interoperability: Unique identifiers (e.g., internal IDs, acceptance numbers) enable cross-database linkages. Users can integrate this data with hospital prescriptions, reimbursement claims, or adverse event monitoring systems to construct end-to-end analytical platforms spanning drug registration, distribution, and clinical use, fostering healthcare big data innovation.

  The CnOpenData Chemical Drug Catalog and Package Insert Database systematically integrates core drug catalog information with comprehensive package insert linkages, covering critical dimensions such as active ingredients, dosage forms/strengths, reference products, ATC codes, marketing statuses, and insert content. It delivers a high-quality, reproducible data foundation for generic drug R&D, healthcare policy analysis, clinical medication guidance, and pharmaceutical information standardization. Leveraging this resource, pharmaceutical enterprises, research institutions, and policymakers can deepen insights into chemical drug markets and advance scientifically informed, efficient drug lifecycle management.

Time Coverage

As of April 2026

Field Display

Sample Data

Update Frequency

Annual updates